6533b7d5fe1ef96bd126523c

RESEARCH PRODUCT

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Matthias PinterMatthias PinterMichael TraunerMarcus-alexander WörnsMarkus Peck-radosavljevicSimona BotaF HuckeRakesh K. JainJens U. MarquardtDan G. DudaWolfgang SieghartPeter R. GalleArndt Weinmann

subject

OncologySorafenibmedicine.medical_specialtybusiness.industryGastroenterologyOriginal Articlesmedicine.disease03 medical and health sciences0302 clinical medicineText miningEndocrinologyOncology030220 oncology & carcinogenesisHepatocellular carcinomaInternal medicineRenin–angiotensin systemmedicine030211 gastroenterology & hepatologyIn patientbusinessmedicine.drug

description

Inhibition of the renin-angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies.The objective of this study was to investigate the effect of RAS inhibitor (RASi) treatment (angiotensin-converting enzyme inhibitors or angiotensin-II-receptor blockers) on survival of patients with hepatocellular carcinoma (HCC).Patients diagnosed with HCC and Child-Pugh A between 1992 and 2013 who received sorafenib, experimental therapy, or best supportive care were eligible for the Vienna cohort. The Mainz cohort included patients with HCC and Child-Pugh A who received sorafenib treatment between 2007 and 2016. The association between RASi and overall survival (OS) was evaluated in univariate and multivariate analyses.In the Vienna cohort, 43 of 156 patients received RASi for hypertension. RASi treatment was associated with longer OS (11.9 vs. 6.8 months (mo);RAS inhibition is associated with longer survival in HCC patients with Child-Pugh class A.

yearjournalcountryeditionlanguage
2016-12-06United European gastroenterology journal
10.1177/2050640617695698https://pubmed.ncbi.nlm.nih.gov/29163965